HARBOUR EQUINE (08377) proposes a discount of approximately 14.89% to issue up to 98.1875 million shares, raising net proceeds of approximately 7.59 million Hong Kong dollars.
Victoria Harbour Stables (08377) announced that on July 13, 2026, the company plans to sell up to 98.1875 million shares of the company, equivalent to approximately 20.00% of the company's existing issued share capital as of the date of this announcement and approximately 16.67% of the company's issued share capital after the issuance and sale of the shares.
HARBOUR EQUINE (08377) announces that on July 13, 2026, the company plans to issue up to 98.1875 million shares for sale, equivalent to approximately 20.00% of the company's existing issued share capital as of the date of this announcement and around 16.67% of the enlarged issued share capital after the issuance. The sale price per share is HK$0.08, representing a discount of approximately 14.89% compared to the closing price of HK$0.094 per share on July 13. It is expected that the total proceeds from the sale could reach up to HK$7.855 million, with an estimated net proceeds of approximately HK$7.59 million. The company plans to use the net proceeds from the sale for (i) repaying existing group loans, accounts payable, and other payables totaling around HK$4.05 million; and (ii) using around HK$3.54 million for the group's general working capital.
Related Articles

GREENTECH INTL(00195): The offeror intends to increase the offer price from HK$0.25 per share to HK$0.45 per share.

Apple Inc. (AAPL.US) acquires some assets of SigScalr, further expanding its layout in AI infrastructure and developer tools.

US Stock Market Move | Will raise up to $340 million to fund colon cancer drug trials Agenus Inc. surged over 130%
GREENTECH INTL(00195): The offeror intends to increase the offer price from HK$0.25 per share to HK$0.45 per share.

Apple Inc. (AAPL.US) acquires some assets of SigScalr, further expanding its layout in AI infrastructure and developer tools.

US Stock Market Move | Will raise up to $340 million to fund colon cancer drug trials Agenus Inc. surged over 130%

RECOMMEND





